Benjamin Bader

This inventor holds 33 USPTO granted patents and 25 published patent applications, plus 4 CIPO patents and 26 EPO patents. Top assignees: Bayer Pharma Aktiengesellschaft, Deutsches Krebsforschungszentrum, Bayer Intellectual Property Gmbh. Active years: 2010-2026.

USPTO Granted Patents = 33 (Patent Applications = 25)

% Patents Active = 51.5

CIPO Patents = 4 (Patent Applications = 23)

EPO Patents = 26 (Patent Applications = 49)

Average Co-Inventor Count = 10.1

ph-index = 5

Forward Citations = 99(Granted Patents)

Company Filing History:

18 out of 380

Bayer Pharma Aktiengesellschaft

patents

10 out of 159

Deutsches Krebsforschungszentrum

patents

9 out of 721

Bayer Intellectual Property Gmbh

patents

4. 8 out of 12,223

Bayer Aktiengesellschaft

patents

5. 2 out of 192

Bayer Schering Pharma Ag

patents

where one patent can have more than one assignee

Years Active: 2010-2026

Loading Chart...

Areas of Expertise:

Cancer Treatment

DGKalpha Inhibitors

Immune Activation

AHR Inhibitors

Heteroaryl Compounds

Morpholin-4-yl Naphthyridines

Triazolopyridines

Imidazopyrazines

Protein Tyrosine Kinase Inhibitors

Pharmaceutical Agents

Kinase Inhibitors

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12673927 - SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION (2026-07-07),

2. 12522594 - 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER (2026-01-13),

3. 12478621 - SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION (2025-11-25),

4. 11998539 - Substituted aminoquinolones as DGKalpha inhibitors for immune activation (2024-06-04),

5. 11964953 - Substituted aminothiazoles as DGKzeta inhibitors for immune activation (2024-04-23),

6. 11795164 - 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer (2023-10-24),

7. 11591311 - 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides (2023-02-28),

8. 11529356 - 2-(morpholin-4-yl)-1,7-naphthyridines (2022-12-20),

9. 11524944 - 2-phenylpyrimidine-4-carboxamides as AHR inhibitors (2022-12-13),

10. 11459312 - Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides (2022-10-04),

11. 11304946 - 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists (2022-04-19),

12. 11040035 - 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides (2021-06-22),

13. 10894784 - Heteroarylbenzimidazole compounds (2021-01-19),

14. 10772893 - 2-(morpholin-4-yl)-1,7-naphthyridines (2020-09-15),

15. 10729680 - 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines (2020-08-04),

As a specialist in innovations, inventions, inventors, patent attorneys, assignees, and patents, I'll assist you with creating the article about inventor Benjamin Bader. Here's a draft structure for the article:

Title: Benjamin Bader - Pioneering Innovator in Pharmaceutical Research

Introduction:

Meet Benjamin Bader, a prolific inventor based in Berlin, Germany, whose groundbreaking work in pharmaceutical research has earned him recognition in the field of immune activation.

Latest Patents:

Benjamin Bader's latest patents include:

1. Substituted aminoquinolones as DGKalpha inhibitors for immune activation - Aminoquinolone compounds designed for treating diacylglycerol kinase alpha regulated disorders.

2. Substituted aminothiazoles as DGKzeta inhibitors for immune activation - Aminothiazole compounds targeting diacylglycerol kinase zeta (DGKζ) regulated disorders.

Career Highlights:

Benjamin Bader has amassed an impressive portfolio of 30 patents throughout his career. He has made significant contributions to the development of pharmaceutical compositions for the treatment and prophylaxis of various diseases related to immune system dysregulation.

Collaborations:

During his tenure, Benjamin Bader has collaborated with esteemed colleagues such as Philip Lienau and Gerhard Siemeister. Together, they have worked at renowned companies in the industry.

Conclusion:

In conclusion, Benjamin Bader's innovative research in pharmaceuticals has paved the way for advancements in immune activation therapies. His dedication to improving treatments for diacylglycerol kinase regulated disorders underscores his impact on the field. Benjamin Bader continues to inspire new generations of inventors with his pioneering work in the realm of patentable innovations.

Feel free to customize the content further to suit your preferences and target audience.